<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03624361</url>
  </required_header>
  <id_info>
    <org_study_id>STAR-II (ISM04EU)</org_study_id>
    <nct_id>NCT03624361</nct_id>
  </id_info>
  <brief_title>MINIject Glaucoma Implant in European Patients</brief_title>
  <acronym>STAR-II</acronym>
  <official_title>A Prospective, Open, Multicentre Clinical Trial With One Cohort Analysing the Efficacy and Safety of MINIject in European Patients With Open Angle Glaucoma Uncontrolled by Topical Hypotensive Medications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iSTAR Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>iSTAR Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the efficacy and safety of the MINIject glaucoma implant and
      Intraocular Pressure (IOP) lowering effects with or without glaucoma medications. The
      procedure will be a stand-alone surgery. Overall, the patient will be asked to perform
      several examinations up to 24 months after surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary endpoint is the 'qualified success' rate at 6 months after surgery greater than
      60%. 'Qualified success' is defined as a diurnal IOP ≤ 21mmHg (millimeter mercury) and &gt;
      5mmHg with a minimum 20% diurnal IOP reduction from baseline with or without the concomitant
      use of allowed glaucoma hypotensive medication at 6 months after surgery
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 23, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>MINIject glaucoma implant CS600 with Dual Operator Delivery Tool</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Qualified success for lowering the IOP</measure>
    <time_frame>at 6 months</time_frame>
    <description>The primary objective is the 'qualified success' rate at 6 months after surgery greater than 60%. 'Qualified success' is defined as a diurnal IOP ≤ 21 mmHg and &gt; 5 mmHg with a minimum 20% diurnal IOP reduction from baseline with or without the concomitant use of allowed glaucoma hypotensive medication at 6 months after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessment of device in terms of adverse events (AEs) and serious adverse events (SAEs) reported during duration of study</measure>
    <time_frame>up to 24 months after surgery</time_frame>
    <description>show safety of the MINIject implant and the procedure used to implant the device</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Glaucoma, Open-Angle</condition>
  <condition>Glaucoma Eye</condition>
  <condition>Intraocular Pressure</condition>
  <arm_group>
    <arm_group_label>Stand-alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive MINIject Glaucoma implant in a stand-alone procedure.
MINIject implant is used to reduce intra-ocular pressure in the eye through a minimally-invasive Glaucoma surgical intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Glaucoma device implantation in a stand-alone procedure</intervention_name>
    <description>MINIject implant is used to reduce intra-ocular pressure in the eye through a minimally-invasive Glaucoma surgical intervention.
The intervention is to be performed as stand-alone surgery.</description>
    <arm_group_label>Stand-alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females, 50 years of age or older.

          -  Diagnosis of primary open angle glaucoma during screening visit or earlier.

          -  Grade 3 (open, 20-35 degrees) or grade 4 (wide open, 35-45 degrees) according to
             Shafer Angle Grading System.

        Exclusion Criteria:

          -  Diagnosis of glaucoma other than primary open angle glaucoma (e.g. angle closure
             glaucoma or secondary open angle glaucoma) in the study eye.

          -  Grade 2 (narrow, 20 degrees), grade 1 (extremely narrow, less or equal to 10 degrees)
             and grade 0 (closed or slit) according to Shafer Angle Grading System.

          -  Neovascular glaucoma in the study eye.

          -  Corneal opacity or iridocorneal angle not visible through gonioscopy prisma in the
             study eye, preventing correct placement of the implant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norbert Pfeiffer, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Mainz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center Hospotalier Universitaire Genoble Alpes</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ludwig-Maximilians-University Munich</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uni-Augenklinik Bochum</name>
      <address>
        <city>Bochum</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44892</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Köln</name>
      <address>
        <city>Köln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Mainz</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augenzentrum Rheine</name>
      <address>
        <city>Rheine</city>
        <zip>48429</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://www.istarmed.com/</url>
    <description>Homepage of the company and information about the product</description>
  </link>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 28, 2018</study_first_submitted>
  <study_first_submitted_qc>August 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2018</study_first_posted>
  <last_update_submitted>May 20, 2019</last_update_submitted>
  <last_update_submitted_qc>May 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Minimally Invasive Glaucoma Surgery</keyword>
  <keyword>Glaucoma Implant</keyword>
  <keyword>Lower IOP</keyword>
  <keyword>IOP</keyword>
  <keyword>Intraocular Pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

